Dr. Daniel Thomas, one of the investigators in our CMML trial, will be moderating our presentation at the ASH Conference on Saturday, discussing the Complete Remission rates those cancer patients achieved with lenz.
"1852 Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia."
In addition, we know that this indication offered certain regulatory incentives. Will our demonstrated success result in an expedited approval or the award of a Priority Review Voucher? If so, will Humanigen announce that news this week, ahead of the conference, and perhaps with the announcement of the recall of our loaned shares?
Also, I see that another of our trial doctors, Dr. Saad Kenderian, who was also very excited about lenzilumab's performance in the LIVE-AIR trial, will also be moderating a separate presentation on Immunotherapies.